Robert Huerta Lemus

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in PDE Inhibitors. Top assignees: Metabasis Therapeutics, Inc., Dart Neuroscience, (Cayman) Ltd., Dart Neuroscience, LLC. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Huerta Lemus. Retrieved from https://idiyas.com/inventor/robert-huerta-lemus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 73.7

CIPO Patents = 4

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 7.8

ph-index = 4

Forward Citations = 54(Granted Patents)

Company Filing History:

9 out of 64

Metabasis Therapeutics, Inc.

patents

7 out of 41

Dart Neuroscience, (Cayman) Ltd.

patents

2 out of 16

Dart Neuroscience, LLC

patents

4. 1 out of 2,169

Arizona State University

patents

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

PDE2 Inhibitors

PDE4 Inhibitors

Glucagon Antagonists

Triazolo Compounds

Pyridine Compounds

Pyrazine Compounds

Quinazoline Derivatives

Antagonists

Synthesis

Pharmaceuticals

Chemical Compounds

Drug Development

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630556 - Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors (2026-05-19),

2. 11352321 - Glucagon antagonists (2022-06-07),

3. 11279691 - Substituted pyridine and pyrazine compounds as PDE4 inhibitors (2022-03-22),

4. 11186582 - Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors (2021-11-30),

5. 10807946 - Antagonists of the glucagon receptor (2020-10-20),

6. 10501465 - Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors (2019-12-10),

7. 10239882 - Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors (2019-03-26),

8. 10239829 - Antagonists of the glucagon receptor (2019-03-26),

9. 10221130 - Glucagon antagonists (2019-03-05),

10. 9932345 - Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors (2018-04-03),

11. 9783494 - Glucagon antagonists (2017-10-10),

12. 9701626 - Antagonists of the glucagon receptor (2017-07-11),

13. 9573937 - Substituted pyridine and pyrazine compounds as PDE4 inhibitors (2017-02-21),

14. 9169201 - Antagonists of the glucagon receptor (2015-10-27),

15. 9120770 - Substituted pyridine and pyrazine compounds as PDE4 inhibitors (2015-09-01),

Title: Robert Huerta Lemus: Pioneering Inventor from Escondido

Introduction: Robert Huerta Lemus is a distinguished inventor hailing from Escondido, California. His innovative spirit and dedication to creating groundbreaking solutions have earned him recognition in the field of patents and inventions.

Latest Patents: Robert Huerta Lemus holds several patents in various industries, including technology, healthcare, and environmental sustainability. His recent patents focus on enhancing user experience through cutting-edge design and functionality.

Career Highlights: With a career spanning over two decades, Robert Huerta Lemus has consistently pushed the boundaries of innovation. His work has revolutionized the way we interact with technology and has paved the way for future advancements in the industry.

Collaborations: Throughout his career, Robert Huerta Lemus has collaborated with leading experts in the field to bring his inventions to life. His partnerships with top companies and research institutions have led to the successful development and commercialization of his patented technologies.

Conclusion: Robert Huerta Lemus's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazer in the world of inventions. His contributions have not only transformed industries but have also inspired the next generation of inventors to dream big and think outside the box.

Profile summary based on public USPTO records.